As of 2026-10-02, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is (24.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 42.18 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -157.2%.
The range of the Relative Valuation is (17.80) - (27.72) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 14.6x | 11.0x |
| Forward P/E multiples | 9.4x - 18.8x | 14.6x |
| Fair Price | (17.80) - (27.72) | (24.14) |
| Upside | -142.2% - -165.7% | -157.2% |
| Date | P/E |
| 2026-09-30 | -22.73 |
| 2026-09-29 | -23.22 |
| 2026-09-28 | -23.56 |
| 2026-09-25 | -22.53 |
| 2026-09-24 | -22.87 |
| 2026-09-23 | -22.92 |
| 2026-09-22 | -23.11 |
| 2026-09-21 | -22.60 |
| 2026-09-18 | -22.18 |
| 2026-09-17 | -22.67 |
| 2026-09-16 | -21.86 |
| 2026-09-15 | -21.80 |
| 2026-09-14 | -21.91 |
| 2026-09-11 | -21.99 |
| 2026-09-10 | -22.02 |
| 2026-09-09 | -22.22 |
| 2026-09-08 | -22.41 |
| 2026-09-04 | -22.99 |
| 2026-09-03 | -23.22 |
| 2026-09-02 | -23.26 |
| 2026-09-01 | -23.10 |
| 2026-08-31 | -23.35 |
| 2026-08-28 | -23.10 |
| 2026-08-27 | -23.34 |
| 2026-08-26 | -23.70 |
| 2026-08-25 | -23.96 |
| 2026-08-24 | -23.83 |
| 2026-08-21 | -24.22 |
| 2026-08-20 | -25.06 |
| 2026-08-19 | -25.64 |
| 2026-08-18 | -25.90 |
| 2026-08-17 | -25.50 |
| 2026-08-14 | -25.50 |
| 2026-08-13 | -24.90 |
| 2026-08-12 | -25.28 |
| 2026-08-11 | -24.76 |
| 2026-08-10 | -24.86 |
| 2026-08-07 | -25.16 |
| 2026-08-06 | -24.70 |
| 2026-08-05 | -24.78 |
| 2026-08-04 | -22.84 |
| 2026-08-03 | -24.30 |
| 2026-07-31 | -23.57 |
| 2026-07-30 | -24.09 |
| 2026-07-29 | -24.60 |
| 2026-07-28 | -25.21 |
| 2026-07-27 | -24.81 |
| 2026-07-24 | -24.40 |
| 2026-07-23 | -24.92 |
| 2026-07-22 | -24.79 |